For decades, the biotech company Genentech has carved out a reputation in the industry as a scientist’s paradise, a place where researchers have developed new therapies in-house and published ...

Following the announcement of a large layoff round in April and a major restructuring initiative unveiled earlier this month, Genentech is sending more jobs to the chopping block. The Roche ...

Genentech, a leading biotechnology company, recently announced the permanent closing of their Cancer Immunology Department. This announcement comes as a major surprise in the scientific community.

What are the best city building games? There’s nothing more relaxing than sitting down for an afternoon of city building games. We’ve lost countless hours lining up buildings just how we like ...

Genentech, a drugmaker based in South San Francisco, is laying off 93 more local workers just months after a 436-worker cut. The company, which is owned by Swiss pharmaceutical giant Roche ...

But biotechnology leader Genentech, in part through its Advancing ... Inclusive Research Site Alliance to nine sites total, building on our existing partnerships to include two new ophthalmology ...

You’ve reached your account maximum for followed topics. Castle-building games like Stronghold offer players a creative outlet to construct impressive fortresses and structures. Games like ...

Roche’s Genentech unit signed a trio of deals this week to add new drug discovery platforms to its repertoire. The three drug discovery deals are with Convelo Therapeutics in neurological ...

Genentech has received Food and Drug Administration approval for its treatment of certain types of lung, liver, skin and soft tissue cancer in adults. The treatment, called Tecentriq Hybreza, can ...

Genentech, a member of the Roche Group (SIX ... OPTIONS XII for the Control of Influenza Congress (September 29 - October 2, Brisbane, Australia). “Building on Xofluza’s established efficacy in ...

The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...